Published in Epidemiology on January 01, 2017
The Authors Respond. Epidemiology (2017) 0.75
For and Against Methodologies: Some Perspectives on Recent Causal and Statistical Inference Debates. Eur J Epidemiol (2017) 0.75
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (2011) 29.14
Causal diagrams for epidemiologic research. Epidemiology (1999) 19.48
A structural approach to selection bias. Epidemiology (2004) 16.44
Simulation study of confounder-selection strategies. Am J Epidemiol (1993) 12.76
Why most discovered true associations are inflated. Epidemiology (2008) 11.22
Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol (2002) 9.76
Instruments for causal inference: an epidemiologist's dream? Epidemiology (2006) 8.50
Fallibility in estimating direct effects. Int J Epidemiol (2002) 8.34
Stepwise selection in small data sets: a simulation study of bias in logistic regression analysis. J Clin Epidemiol (1999) 6.66
Beyond the intention-to-treat in comparative effectiveness research. Clin Trials (2011) 2.65
Invited Commentary: Causal diagrams and measurement bias. Am J Epidemiol (2009) 2.06
Causal inference from longitudinal studies with baseline randomization. Int J Biostat (2008) 1.69
Randomized trials analyzed as observational studies. Ann Intern Med (2013) 1.60
International conference on harmonisation; guidance on statistical principles for clinical trials; availability--FDA. Notice. Fed Regist (1998) 1.60
Matched designs and causal diagrams. Int J Epidemiol (2013) 1.08
Limitations of individual causal models, causal graphs, and ignorability assumptions, as illustrated by random confounding and design unfaithfulness. Eur J Epidemiol (2015) 0.93
Ignorability and bias in clinical trials. Stat Med (1999) 0.89
Structural Approach to Bias in Meta-analyses. Res Synth Methods (2012) 0.83
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet (2006) 31.79
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (2011) 29.14
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med (2011) 15.02
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Constructing inverse probability weights for marginal structural models. Am J Epidemiol (2008) 12.39
Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (2008) 11.08
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet (2002) 9.66
Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med (2008) 9.39
How should meta-regression analyses be undertaken and interpreted? Stat Med (2002) 8.96
Fallibility in estimating direct effects. Int J Epidemiol (2002) 8.34
Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet (2005) 7.89
Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol (2007) 7.00
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (2011) 6.80
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet (2005) 6.60
Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet (2010) 6.02
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85
Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol (2003) 5.81
A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med (2006) 5.43
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med (2011) 5.35
Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis (2005) 5.20
Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed (2004) 5.11
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol (2007) 4.96
Evaluation of networks of randomized trials. Stat Methods Med Res (2007) 4.70
Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol (2005) 4.44
Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA (2007) 4.40
The birth weight "paradox" uncovered? Am J Epidemiol (2006) 4.38
Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med (2008) 4.34
Interpretation of random effects meta-analyses. BMJ (2011) 4.32
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31
Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol (2002) 4.30
Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med (2010) 4.27
Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. Ann Intern Med (2013) 4.02
Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med (2012) 3.63
NHS waiting lists and evidence of national or local failure: analysis of health service data. BMJ (2003) 3.60
Epidemiology, data sharing, and the challenge of scientific replication. Epidemiology (2009) 3.49
Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ (2006) 3.47
The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. Am J Epidemiol (2007) 3.40
Secular trends in mortality by stroke subtype in the 20th century: a retrospective analysis. Lancet (2002) 3.29
A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics (2006) 3.23
A road map for efficient and reliable human genome epidemiology. Nat Genet (2006) 3.21
Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials (2005) 3.19
Gout and risk of Parkinson disease: a prospective study. Neurology (2007) 3.09
Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis (2008) 3.09
Recent developments in meta-analysis. Stat Med (2008) 2.97
Accuracy of magnetic resonance imaging for the diagnosis of multiple sclerosis: systematic review. BMJ (2006) 2.95
Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol (2003) 2.90
Sensitivity analyses for unmeasured confounding assuming a marginal structural model for repeated measures. Stat Med (2004) 2.87
Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res (2011) 2.83
Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet (2006) 2.72
Graphical tools for network meta-analysis in STATA. PLoS One (2013) 2.66
Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study. AIDS (2010) 2.66
Causal directed acyclic graphs and the direction of unmeasured confounding bias. Epidemiology (2008) 2.60
Synthesizing evidence on complex interventions: how meta-analytical, qualitative, and mixed-method approaches can contribute. J Clin Epidemiol (2013) 2.59
Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology (2008) 2.51
When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. Int J Biostat (2010) 2.50
Intervening on risk factors for coronary heart disease: an application of the parametric g-formula. Int J Epidemiol (2009) 2.48
A critical evaluation of statistical approaches to examining the role of growth trajectories in the developmental origins of health and disease. Int J Epidemiol (2013) 2.47
Strengthening the reporting of genetic association studies (STREGA): an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement. J Clin Epidemiol (2009) 2.45
STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med (2009) 2.39
Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. Stat Med (2004) 2.26
A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol (2009) 2.26
Commentary: A structural approach to Berkson's fallacy and a guide to a history of opinions about it. Int J Epidemiol (2014) 2.23
Commentary: how to report instrumental variable analyses (suggestions welcome). Epidemiology (2013) 2.22
Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol (2011) 2.20
Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. Am J Epidemiol (2005) 2.20
Was the economic crisis 1997-1998 responsible for rising suicide rates in East/Southeast Asia? A time-trend analysis for Japan, Hong Kong, South Korea, Taiwan, Singapore and Thailand. Soc Sci Med (2009) 2.18
Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer (2005) 2.16
Strategies for multiple imputation in longitudinal studies. Am J Epidemiol (2010) 2.15
Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. Am J Epidemiol (2009) 2.15
Treating individuals 4: can meta-analysis help target interventions at individuals most likely to benefit? Lancet (2005) 2.09
Array CGH in patients with learning disability (mental retardation) and congenital anomalies: updated systematic review and meta-analysis of 19 studies and 13,926 subjects. Genet Med (2009) 2.09
An empirical comparison of methods for meta-analysis of diagnostic accuracy showed hierarchical models are necessary. J Clin Epidemiol (2008) 2.07
A Comparison of Agent-Based Models and the Parametric G-Formula for Causal Inference. Am J Epidemiol (2017) 2.05
Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr (2012) 2.03
Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS One (2013) 2.03
Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model. Am J Epidemiol (2007) 2.00
Characteristics of meta-analyses and their component studies in the Cochrane Database of Systematic Reviews: a cross-sectional, descriptive analysis. BMC Med Res Methodol (2011) 1.97
We are number one but nobody cares-that's good. Epidemiology (2012) 1.97
Conceptual and technical challenges in network meta-analysis. Ann Intern Med (2013) 1.92
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis (2009) 1.86
Confounding adjustment via a semi-automated high-dimensional propensity score algorithm: an application to electronic medical records. Pharmacoepidemiol Drug Saf (2011) 1.85
Adjusting mortality for loss to follow-up: analysis of five ART programmes in sub-Saharan Africa. PLoS One (2010) 1.84
Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther (2008) 1.83
STrengthening the REporting of Genetic Association studies (STREGA)--an extension of the STROBE statement. Eur J Clin Invest (2009) 1.82
Instrumental variable estimation of causal risk ratios and causal odds ratios in Mendelian randomization analyses. Am J Epidemiol (2011) 1.79
Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med (2010) 1.78
Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol (2012) 1.76
Opportunistic and systematic screening for chlamydia: a study of consultations by young adults in general practice. Br J Gen Pract (2006) 1.75
Comparative effectiveness of dynamic treatment regimes: an application of the parametric g-formula. Stat Biosci (2011) 1.73
Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. J Clin Epidemiol (2005) 1.72
Evaluation of inconsistency in networks of interventions. Int J Epidemiol (2013) 1.72
Obstacles and opportunities in meta-analysis of genetic association studies. Genet Med (2005) 1.71